Entity family
Clinical therapies and care approaches used to manage a condition. Examples include immunotherapy, radiotherapy, rehabilitation.
Showing 2,101–2,160 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
…n), then monthly during maintenance. Selected patients received involved-field radiotherapy. Primary endpoints were recommended dose and safety based on ad…
…atients have typically already received several rounds of prior cancer treatments with diminishing returns, presenting with rapidly advancing dis…
…romising 50% response in the study population who progressed on immunotherapy. Mechanism of the response was investigated through analysis of…
…gressive malignancies with limited effective treatment options. Immune checkpoint inhibitors (ICIs) have demonstrated limited clinical activity in these tum…
…rent immune and targeted therapies. We previously reported that adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) could ach…
…Background Adoptive T cell therapy with expanded tumor-infiltrating lymphocytes (TILs) and PD-1 ta…
… 2018–2022 (median follow-up 26.5 months), all of whom received platinum-based chemotherapy (± bevacizumab) in first- or second-line settings; 86 patients …
…vivo. In the CT-26 syngeneic mouse model. HDM2021 combined with anti-PD1 treatment induced statistically significant tumor growth inhibition (TGI …
…r-targeting immune responses. Combining BNT162b2 treatment with anti-PD-L1 therapy yielded a substantial therapeutic impact, even in ‘cold tumors’…
…notherapies, with further significant enhancement observed with combination therapy. These antitumor effects were not significantly reduced under C…
… The effects of ancestry on emerging therapy approaches such as chimeric antigen receptor (CAR) T cell therapy and proteolysis-targeting chimeras (PROTACs) therapy are also b…
…une checkpoint inhibitors (ICIs), especially when combined with radiation therapy (RT), have shown promise, and tumor microenvironment (TME) immu…